


CaixaResearch



This form is only for informational purposes.

Applications will be submitted using the application form on the programme's website (https://grants.lacaixafoundation.org/).

Applications delivered by paper or any other means will not be accepted.

General Data and Proposal Information

Application Details

Call Name text, pre-filled in with the name of the call.

Application number application number assigned by the system.

Proposal Title textbox, 150 characters.

Proposal Description textbox, 200 characters.

Proposal Acronym textbox, 20 characters.

Project Leader text, pre-filled in with the name and surnames of the user submitting the form.

Host Organization text, pre-filled in with the name of the PL's Host Organization.

Faculty or Research Center (if applicable) textbox, 100 characters, optional.


Classification of the Application

Select the business area

- » Therapeutic
- » Medical Devices
- » Diagnostics
- » Digital Health

Select the scientific area


- » Molecular and Structural Biology and Biochemistry
- » Genetics, Genomics, Bioinformatics and Systems Biology
- » Cellular and Developmental Biology
- » Physiology, Pathophysiology and Endocrinology
- » Neurosciences and Neural Disorders
- » Immunity and Infection
- » Diagnostic Tools, Therapies and Public Health
- » Applied life Sciences and Non-Medical Biotechnology



Select the relevant subareas of your project Options available depending on the selection on the previous question:

| 1 | Molecular and Structural Biology and Biochemistry | | | | | | | |
|-------------|---------------------------------------------------------------------------|--|--|--|--|--|--|--|
| 1 1 | Molecular and Structural Biology and Biochemistry Molecular interactions | | | | | | | |
| 1 2 | General biochemistry and metabolism | | | | | | | |
| 1_3 | DNA synthesis, modification, repair, recombination and degradation | | | | | | | |
| 1 4 | RNA synthesis, processing, modification and degradation | | | | | | | |
| 1_5 | Protein synthesis, modification and turnover | | | | | | | |
| 1_5 1_6 | Lipid synthesis, modification and turnover | | | | | | | |
| 1_7 | Carbohydrate synthesis, modification and turnover | | | | | | | |
| | | | | | | | | |
| 1_8 | Biophysics (e.g. transport mechanisms, bioenergetics, fluorescence) | | | | | | | |
| 1_9 | Structural biology (crystallography and EM) | | | | | | | |
| 1_10 | Structural biology (NMR) | | | | | | | |
| 1_11 | Biochemistry and molecular mechanisms of signal transduction | | | | | | | |
| 2 | Genetics, Genomics, Bioinformatics and Systems Biology | | | | | | | |
| 2_1 | Genomics, comparative genomics, functional genomics | | | | | | | |
| 2 2 | Transcriptomics | | | | | | | |
| 2_3 | Proteomics | | | | | | | |
| 2_4 | Metabolomics | | | | | | | |
| 2_5 | Glycomics | | | | | | | |
| 2_6 | Molecular genetics, reverse genetics and RNAi | | | | | | | |
| 2_7 | Quantitative genetics | | | | | | | |
| 2 8 | Epigenetics and gene regulation | | | | | | | |
| 2_9 | Epigenetics and gene regulation Genetic epidemiology | | | | | | | |
| 2 10 | Bioinformatics | | | | | | | |
| 2 11 | Computational biology | | | | | | | |
| 2 12 | Biostatistics | | | | | | | |
| 2_13 | Systems biology | | | | | | | |
| 2 14 | Biological systems analysis, modelling and simulation | | | | | | | |
| | | | | | | | | |
| 3 | Cellular and Developmental Biology | | | | | | | |
| 3_1 | Morphology and functional imaging of cells | | | | | | | |
| 3_2 | Cell biology and molecular transport mechanisms | | | | | | | |
| 3_3 | Cell cycle and division | | | | | | | |
| 3_4 | Apoptosis | | | | | | | |
| 3_5 | Cell differentiation, physiology and dynamics | | | | | | | |
| 3_6 | Organelle biology | | | | | | | |
| 3_7 | Cell signalling and cellular interactions | | | | | | | |
| 3_8 | Signal transduction | | | | | | | |
| 3_9 | Development, developmental genetics, pattern formation and embryology | | | | | | | |
| 3_10 | Cell genetics | | | | | | | |
| 3_11 | Stem cell biology | | | | | | | |
| 3_12 | Morphology and functional imaging of cells | | | | | | | |
| 4 | Physiology Pathonhysiology and Endosvinology | | | | | | | |
| 4 | Physiology, Pathophysiology and Endocrinology | | | | | | | |
| 4_1 | Organ physiology and pathophysiology Endocrinology | | | | | | | |
| 4_3 | | | | | | | | |
| 4_4 | Ageing Matabalism biological basis of matabalism related disorders | | | | | | | |
| 4_5 | Metabolism, biological basis of metabolism related disorders | | | | | | | |
| 4_6 | Cancer and its biological basis | | | | | | | |

| 4_7 | Cardiovascular diseases | | | | | | |
|------|-----------------------------------------------------------------------------------------------|--|--|--|--|--|--|
| 4_8 | Non-communicable diseases (except for neural/psychiatric, immunity-r | | | | | | |
| _ | metabolism-related disorders, cancer and cardiovascular diseases) | | | | | | |
| | | | | | | | |
| 5 | Neurosciences and Neural Disorders | | | | | | |
| 5_1 | Neuroanatomy and neurophysiology | | | | | | |
| 5_2 | Molecular and cellular neuroscience | | | | | | |
| 5_3 | Neurochemistry and neuropharmacology | | | | | | |
| 5_4 | Sensory systems (e.g. visual system, auditory system) | | | | | | |
| 5_5 | Mechanisms of pain | | | | | | |
| 5_6 | Developmental neurobiology | | | | | | |
| 5_7 | Cognition (e.g. learning, memory, emotions, speech) | | | | | | |
| 5_8 | Behavioural neuroscience (e.g. sleep, consciousness, handedness) | | | | | | |
| 5_9 | Systems neuroscience | | | | | | |
| 5_10 | Neuroimaging and computational neuroscience | | | | | | |
| 5_11 | Neurological disorders (e.g. Alzheimer's disease, Huntington's disease, Parkinson's disease) | | | | | | |
| 5_12 | Psychiatric disorders (e.g. schizophrenia, autism, Tourette's syndrome, obsessiv | | | | | | |
| | compulsive disorder, depression, bipolar disorder, attention deficit hyperactivity disorder) | | | | | | |
| | | | | | | | |
| 6 | Immunity and Infection | | | | | | |
| 6_1 | Innate immunity and inflammation | | | | | | |
| 6_2 | Adaptive immunity | | | | | | |
| 6_3 | Phagocytosis and cellular immunity | | | | | | |
| 6_4 | Immunosignalling | | | | | | |
| 6_5 | Immunological memory and tolerance | | | | | | |
| 6_6 | Immunogenetics | | | | | | |
| 6_7 | Microbiology | | | | | | |
| 6_8 | Virology | | | | | | |
| 6_9 | Bacteriology | | | | | | |
| 6_10 | Parasitology | | | | | | |
| 6_11 | Prevention and treatment of infection by pathogens (e.g. vaccination, antibiotics, fungicide) | | | | | | |
| 6_12 | Biological basis of immunity related disorders (e.g. autoimmunity) | | | | | | |
| | | | | | | | |
| 7 | Diagnostic Tools, Therapies and Public Health | | | | | | |
| 7_1 | Medical engineering and technology | | | | | | |
| 7_2 | Diagnostic tools (e.g. genetic, imaging) | | | | | | |
| 7_3 | Pharmacology, pharmacogenomics, drug discovery and design, drug therapy | | | | | | |
| 7_4 | Analgesia and Surgery | | | | | | |
| 7_5 | Toxicology | | | | | | |
| 7_6 | Gene therapy, cell therapy, regenerative medicine | | | | | | |
| 7_7 | Radiation therapy | | | | | | |
| 7_8 | Health services, health care research | | | | | | |
| 7_9 | Public health and epidemiology | | | | | | |
| 7_10 | Environment and health risks, occupational medicine | | | | | | |
| 7_11 | Medical ethics | | | | | | |
| | | | | | | | |
| 8 | Applied life Sciences and Non-Medical Biotechnology | | | | | | |
| 8_1 | Applied genetic engineering, transgenic organisms, recombinant proteins, biosensor | | | | | | |
| 8_2 | Synthetic biology, chemical biology and new bio-engineering concepts | | | | | | |
| 8_3 | Food sciences | | | | | | |



Information for "la Caixa" Foundation

This information will only be used for monitoring/statistical purposes

Are you or any member of your group applying to any other "la Caixa" Foundation call (research, innovation projects and fellowships)?

- » Yes
- » No

Please indicate the application code (such as HR20-00001, Cl18-00001...) for each of the proposals where you or a member of your group apply

Application code Do you or any member of your group have an ongoing project with "la Caixa" (research, innovation projects and fellowships)? >> Yes >> No Please indicate the application code (such as LCF/PR/HR17/52150017) for each of the proposals where you or a member of your group apply Application code Have you submitted a previous application to Caixalmpulse/CaixaResearch Consolidate call? >> Yes >> No

Which of the two stages of selection did the proposal achieve?

- » Letter of Intent (1st stage)
- » Full Proposal (2nd stage)

Provide the Caixalmpulse codes that were assigned to your proposal in previous attempts (e.g. CL91-XXX or CF91-XXX)

Application code

Select the option that best suits your proposal

- » Cardiovascular
- » Experimental and mathematical sciences
- » Infectious diseases
- » Medical sciences
- » Neurosciences
- » Oncology

» Other health sciences

General information about the project

| Does the | project | have an | Intellectual | Property | / Protection | Strategy? |
|----------|---------|---------|--------------|-----------------|--------------|-----------|
|----------|---------|---------|--------------|-----------------|--------------|-----------|

- » Yes
- » No

Describe the current IP strategy to protect your Asset(s). Include patent codes if available. Textbox.

Time to market

- » Over 6 years
- » Between 4 and 6 years
- » Between 2 and 4 years
- » Less than 2 years

Technology Readiness Level

Please indicate the Technology Readiness level (reference).

| 0 | 1 | 0 | 4 | 0 | 7 |
|---|---|---------|---|---------|---|
| 0 | 2 | \circ | 5 | \circ | 8 |
| 0 | 3 | 0 | 6 | 0 | 9 |

Has the Asset(s) been transferred to a Spin-off company?

- » Yes
- » No

Information about the Spin-off (name, website, etc). Textbox, 150 characters.

Has your Asset(s) been under evaluation by other funding programmes prior to this call (an object of research grants or other innovation or acceleration programmes)? Please detail the most relevant ones


Textbox, 500 characters, optional.

Amount requested from the "la Caixa" Foundation

Total amount foreseen in the development plan of your project

Describe the core idea of your application in one sentence Textbox, 150 characters.

Abstract (proposal summary) Textbox, 1500 characters.



Letter of Intent

Aim and potential impact

Aim of the project

What is the unmet need you aim to address and why is it timely and relevant? What potential impact will your solution have in terms of affordability, scalability and sustainability? Who will be the main beneficiaries of your solution? Textbox, 1500 characters.

Scientific rationale and implementation

What are the scientific fundamentals underlying your idea?

Have you performed a proof of concept validation? Textbox, 1500 characters.

Describe how the Project's Leader knowledge and experience in field of the Asset(s) would contribute to the success of the Project.

Discuss it in the context of the composition and the relevancy of the rest of the team members. Textbox, 1000 characters.

Development roadmap and market potential

Innovation Transfer milestones

Describe the specific innovation **transfer milestones** you wish to achieve by participating in this Call in terms of time-to-market.

Textbox, 1500 characters.

Commercialisation

According to the stage of development of the Asset(s), what are the identified determinants that currently condition its successful progression to the commercialisation phases? 1000 characters.

Market and market access

Market size and segment; buyers, end-users and relevant stakeholders. Textbox, 1500 characters.

Competitor solutions

What are the competitor solutions that currently address the specific problem you aim to solve? What is the innovation of your solution compared to those other approaches? Textbox, 1500 characters.